Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World September 17, 2010 Andrew Turley	Free trade could throttle generics from India International agreements on intellectual property threaten the flow of generic HIV drugs from India to developing countries, according to a new report.
Chemistry World November 28, 2008 Matt Wilkinson	EU claims pharma delaying tactics cost 3 billion euros Pharmaceutical manufacturers have been criticised by the EU competition commission for slowing the entry of generic medicines to the market.
Chemistry World July 11, 2012 Ling Wang	China Targets Patented Drugs with Law Change China has altered its licensing laws to allow domestic pharmaceutical companies to make cheap generic copies of patented drugs under certain circumstances.
Salon.com June 1, 2001 Daryl Lindsey	The AIDS-drug warrior Outspoken AIDS-drug activist Jamie Love says pharmaceutical companies must be forced to yield their patents to save hundreds of thousands of lives. Is he a visionary -- or a dangerous radical?
Chemistry World May 15, 2015 Rebecca Trager	Trade agreement could limit access to medicines A leaked draft of a trade agreement under negotiation among 12 Pacific rim countries, including the US and Japan, contains language that could delay the entrance of generic competition for much-needed medicines.
The Motley Fool December 14, 2006 Stephen Albainy-Jenei	Merck Gets Punk'd by Thailand Thailand issues a compulsory license to manufacture a generic version of Merck's patented AIDS drug. This is an act of humanitarian aid, but it is also an avenue for price and profit erosion worldwide.
Pharmaceutical Executive April 1, 2014	Whatever Happened To Faster Reimbursement For Generics In Europe? The plan to accelerate generic pricing and reimbursement has become another tragic European casualty.
Salon.com March 19, 2001 Ben Barber	Fighting the plague The World Trade Organization steps into Africa's AIDS crisis, creating incentives for pharmaceutical companies to give some of their drugs away.
Pharmaceutical Executive June 1, 2014	Hopes High as EU Heads Into Leadership Change The principal drug industry associations in Europe launched a call in mid-May for "an integrated European industrial policy for the pharmaceuticals sector."
Chemistry World November 21, 2008 Pete Mitchell	UK drug price deal finalised The new deal is guaranteed to continue for five years - a great relief to the industry.
Pharmaceutical Executive August 1, 2012 Carol Ann Williams	Data Exclusivity: Making the Case As the scope and complexity of registration information demanded by regulators increases, protection of that know-how has become a critical differentiator in the "go" or "no go" calculation on whether to invest in a new medicine.
Salon.com May 1, 2001 Daryl Lindsey	Amy and Goliath A first-year law student brought a giant pharmaceutical to its knees. But will her victory for South Africa's AIDS sufferers deprive the world of new medicines?
Chemistry World October 23, 2009 Matt Wilkinson	What's in a pill? Buying cheap drugs over the internet is well known to be a risky business. But the sinister menace of the 'falsified' active pharmaceutical ingredient gets far less publicity.
The Motley Fool January 31, 2007 Brian Lawler	You're Only Hurting Yourself, Thailand Thailand's decision to allow generics could do more harm than good. Investors, take note.
Pharmaceutical Executive September 1, 2005 Sarah Houlton	Global Report: Kids 'R' EU After years of delay, the European Parliament is ready to vote on pediatric-testing legislation.
Pharmaceutical Executive September 1, 2013	T-TIPing the Balance in Industry's Favor By the start of 2014, industry expects to have a clearer idea of how far the US-EU free trade pact is going.
Chemistry World August 17, 2015 Anthony King	Greek crisis puts pressure on pharmaceuticals Supplies of critical drugs to Greek pharmacies have become sparse and erratic as the economic crisis squeezes public spending
Reason February 2002 Mike Godwin	Prescription Panic How the anthrax scare challenged drug patents...
Chemistry World June 23, 2010 Sarah Houlton	A smaller future for big pharma? Cutting the amount spent on medicines may be an easy way for governments to help balance the books in the short term, but in the long run it will impact the ability to discover new medicines.
Chemistry World March 20, 2012 Rajesh Parishwad	India Green Lights Production of Patented Cancer Drug For the first time India has invoked a 'compulsory license' clause to cut the cost of a patented anti-cancer drug by allowing another company to manufacture the therapy.
Pharmaceutical Executive October 1, 2011 Ansis Helmanis	IP: Securing a Global Consensus--Can Industry Do It Again? Dr. Harvey Bale's long career in defense of IP took him from service as Assistant US Trade Representative to high-profile industry association posts.
The Motley Fool March 14, 2008 Stephen Albainy-Jenei	The War on (the Cost of) Drugs Pharmaceutical companies could be hurt by countries disregarding drug patents.
The Motley Fool October 18, 2010 Brian Orelli	Pfizer Flexes Its Generic Muscles The pharma giant moves farther into generic drugs.
Chemistry World March 4, 2013 Andy Extance	UK considers patent rule change for trials The UK has announced plans to amend aspects of its patent law that may be encouraging pharma companies to run their clinical trials in other countries.
Chemistry World October 8, 2015 Rebecca Trager	Controversial new trade deal finalised The far-reaching Trans-Pacific Partnership trade agreement was finalized on 5 October by leaders from the US and 11 other Pacific rim countries, but there has been backlash.
Chemistry World July 25, 2012	Drugs Top EU Counterfeit Imports In 2011, EU customs officers stopped 115 million products suspected of violating intellectual property rights. Medicines top the list, accounting for 24% of those items.
Pharmaceutical Executive September 1, 2014	Peril, Not Progress on Transatlantic Trade Deal Pharma hopes for a deal are fading as the once-hot TTIP talks seem to be on the fizzle in Europe.
Chemistry World September 14, 2007 Peter Mitchell	European Patents Set to Get Cheaper Patents valid across many European countries will soon be much easier and cheaper to register, with the coming into force of the so-called London Agreement.
The Motley Fool April 25, 2006 Brian Gorman	Pharma Plays With Fire Drugmakers' short-term gain could lead to long-term pain.
The Motley Fool April 26, 2007 Brian Lawler	Brazil's Boneheaded Drug Move Brazil already receives a steep discount on the price that Merck charges it for its HIV compounds. Nevertheless, it wants still lower prices to help reduce the government's costs associated with supplying drugs to those living with HIV/AIDS.
Chemistry World May 21, 2009 Matt Wilkinson	Big Pharma set for generics boost Pharmaceutical firms have been rushing to ensure they minimize their losses by expanding their generics businesses and reach into emerging markets.
Chemistry World July 10, 2009 Sarah Houlton	Branded drugs' competition-free days numbered Authorities in the US and Europe are to look carefully at the tactics pharmaceutical firms use to delay competition from generic versions of their branded drugs.
The Motley Fool March 28, 2005 Brian Gorman	A Passage to India? Changes in India's patent law could create new dynamics for the biotech and pharmaceutical industries. Investors should be on the lookout for the firms that seek to leverage these new opportunities.
Pharmaceutical Executive September 1, 2012 Stan Bernard	The Payer C Change: From Customers to Competitors "Payers have evolved to become powerful global contenders with pharma for increasingly limited funding of drug budgets." Understanding why and how this payer shift to dominance occurred is critical for pharmaceutical professionals in adjusting their business model.
The Motley Fool March 15, 2007 Brian Lawler	It's All Good for Drugmakers With the whole drug industry growing so strongly, those looking for a safe place to park their investing dollars would be smart to take a look at some of the largest generic drugmakers.
Chemistry World June 18, 2008 Ananyo Bhattacharya	Deal on NHS drugs set to trim pharma profits An agreement between the UK government and the pharmaceutical industry will cut around five per cent off the cost of medicines sold to the National Health Service
Chemistry World August 6, 2007 Victoria Gill	Novartis Loses Indian Patent Law Case Swiss drug firm Novartis has lost its legal case against the Indian government, who it had accused of 'unconstitutional' patent law practices. The ruling sets an important precedent that will cheer the flourishing generics market in the country.
Knowledge@Wharton	Encouraging the Development of Drugs for Poor, not Just Rich, Nations The current system rewards research into diseases that afflict rich countries, but creating new medicines for the rest of the world and finding ways to pay for them will demand new partnerships, according to panelists at the recent conference "Pharmaceutical Innovation in a Global Economy."
Chemistry World March 25, 2010 Rebecca Trager	Big pharma scores in US healthcare reform President Obama has signed the biggest US healthcare reform since the 1960s, and although it is largely seen as a victory for the pharmaceutical industry, some analysts are characterising it as a 'double-edged sword'.
Managed Care September 2006	Payers, Consumers Benefit as Patents Expire The generic drug market seems ready to explode, according to reports from IMS Health and the Generic Pharmaceuticals Association.
Chemistry World February 15, 2007 Victoria Gill	Novartis Contests India's Patent Law Swiss pharmaceutical company Novartis has accused the Indian government of failing to comply with WTO rules after it refused to grant the company a patent on its cancer drug Glivec.
Chemistry World July 25, 2012	Pharma Industry May Suffer as India Looks to Generics India plans to provide free generic drugs to half its population.
Chemistry World August 23, 2012 Simon Campbell	Protecting patients at all costs A new funding model is urgently required to deliver innovative medicines that meet the medical needs of the 21st century and contribute to economic growth.
The Motley Fool December 12, 2007 Brian Lawler	Patent Bill Is No Panacea A new bill that was meant to strengthen the patent and other intellectual-property rights of drugmakers doesn't do enough to encourage pharma innovation.
Chemistry World December 1, 2006 Arthur Rogers	EU Approves 54 Billion Euro Science Plan The European Parliament has finally approved the Seventh Framework Research Program, which promises to distribute 54 billion euro of science funding over the next seven years.
Pharmaceutical Executive November 1, 2008 Sarah Houlton	Cash Flow Woes in EU In Europe, the wildly different attitudes toward healthcare across the different member states make for a complex pharmaceutical marketplace.
Pharmaceutical Executive July 1, 2011	Holy Surge of Enthusiasm! While Europe's EFPIA preaches about embracing change, much remains to be done to prove the adjustment in philosophy.
The Motley Fool February 22, 2005 Brian Gorman	Novartis Embraces Generics The company is taking a different path from its branded pharmaceutical peers. The company's strategy may make its stock worth a closer look.
Chemistry World May 23, 2012 Andy Extance	Drug watchdogs mark out global territory The US Food and Drug Administration has published plans to ensure that American citizens continue to enjoy access to safe drugs, even as the regulatory pressures of globalization grow.
The Motley Fool November 27, 2006 Brian Lawler	Teva and Pfizer Make Up The companies decide to play nice over generic versions of two of Pfizer's drugs.